Advertisement

Lipid-lowering drugs and homocysteine

A comparison between statins and other lipid-lowering drugs
      The benefits of lowering cholesterol levels have been well established in large clinical trials both in the secondary and the primary settings. In multiple studies, total plasma homocysteine has been shown to be increased in subjects with coronary artery disease and is considered as an emerging risk factor. B-group vitamins decrease plasma homocysteine levels. Other pharmacological agents are also known to alter the concentration of plasma homocysteine. Among them, lipid-lowering drugs have been shown to modify homocysteine levels. An increasing effect on homocysteine concentrations may counteract the favorable effect on cholesterol levels.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • De Lorgeril M.
        • Salen P.
        • Paillard F.
        • Lacan P.
        • Richard G.
        Lipid-lowering drugs and homocysteine.
        Lancet. 1999; 353: 209-210
        • Landray M.J.
        • Townend J.N.
        • Martin S.
        • Martin U.
        • Wheeler D.C.
        Lipid-lowering drugs and homocysteine.
        Lancet. 1999; 353: 1974-1975
        • Dierkes J.
        • Westphal S.
        • Luley C.
        Serum homocysteine increases after therapy with fenofibrate or bezafibrate.
        Lancet. 1999; 354: 219-220
        • Malik J.
        • Melenowsky V.
        • Wichterle D.
        • Haas T.
        • Simek J.
        • Ceska R.
        • Hradec J.
        Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial—FAT).
        Cardiovasc. Res. 2001; 52: 290-298
        • Giral P.
        • Bruckert E.
        • Jacob N.
        • Chapman M.J.
        • Foglietti M.J.
        • Turpin G.
        Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.
        Atherosclerosis. 2001; 154: 421-427
        • Bissonnette R.
        • Treacy E.
        • Rozen R.
        • Boucher B.
        • Cohn J.S.
        • Genest J.
        Fenofibrate raises plasma homocysteine levels in the fasted and fed states.
        Atherosclerosis. 2001; 155: 455-462
        • Dierkes J.
        • Westphal S.
        • Kunstmann S.
        • Banditt P.
        • Lossner A.
        • Luley C.
        Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate.
        Atherosclerosis. 2001; 158: 161-164
        • Stulc T.
        • Melenovsky V.
        • Graurova B.
        • Kozich V.
        • Ceska R.
        Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.
        Nutrition. 2001; 17: 721-723
        • Westphal S.
        • Dierkes J.
        • Luley C.
        Effects of fenofibrate and gemfibrozil on plasma homocysteine.
        Lancet. 2001; 358: 39-40
        • Melenovsky V.
        • Malik J.
        • Wichterle D.
        • Simek J.
        • Pisarikova A.
        • Skrha J.
        • et al.
        Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
        Am. Heart J. 2002; 144: e6
        • Playford D.A.
        • Watts G.F.
        • Croft K.D.
        Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes.
        Atherosclerosis. 2003; 168: 169-179
        • Jonkers I.J.A.M.
        • de Man F.H.A.F.
        • Onkenhout W.
        • van der Laarse A.
        • Smelt A.H.
        Implication of fibrate therapy for homocysteine.
        Lancet. 1999; 354: 1208
        • Harats D.
        • Yodfat O.
        • Doolman R.
        • Gavendo S.
        • Marko D.
        • Shaish A.
        • et al.
        Homocysteine elevation with fibrates: is it a class effect?.
        Isr. Med. Assoc. J. 2001; 3: 243-246
        • Davis M.
        • Atwal A.S.
        • Nair D.R.
        • Jagroop I.A.
        • Seifalian A.M.
        • Mikhailidis D.P.
        • et al.
        The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study.
        Curr. Med. Res. Opin. 2000; 16: 198-204
        • Sasaki S.
        • Kuwahara N.
        • Kunitomo K.
        • Harada S.
        • Yamada T.
        • Azuma A.
        • et al.
        Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipidemia.
        Am. J. Cardiol. 2002; 89: 386-389
        • Miltiadous G.
        • Papakostas J.
        • Chasiotis G.
        • Seferiadis K.
        • Elisaf M.
        Statins and homocysteine.
        Atherosclerosis. 2003; 166: 199-200
        • MacMahon M.
        • Kirkpatrick C.
        • Cummings C.E.
        • Clayton A.
        • Robunson P.J.
        • Tomiak R.H.
        • et al.
        A pilot study with simvastatin and folic acid/Vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH).
        Nutr. Metab. Cardiovasc. Dis. 2000; 10: 195-203
        • Lűftjohann D.
        • Sigit J.I.
        • Locatelli S.
        • von Bergmann K.
        High-dose simvastatin (80 mg/day) decreases plasma concentrations of total homocysteine in patients with hypercholesterolemia.
        Atherosclerosis. 2001; 155: 265-266
        • Vigna G.B.
        • Donega P.
        • Zanca R.
        • Barban A.
        • Passaro A.
        • Pansini F.
        • et al.
        Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial.
        Metabolism. 2002; 51: 1463-1470
        • Haak E.
        • Abletshauser C.
        • Weber S.
        • et al.
        Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia.
        Atherosclerosis. 2001; 155: 395-401
        • Malyszko J.
        • Malyszko J.S.
        • Brzósko S.
        • Pawlak K.
        • Mysliwiec M.
        Effects of fluvastatin on homocysteine and serum lipids in kidney allograft recipients.
        Ann. Transplant. 2002; 7: 52-54
        • Capecchi P.L.
        • Lazzerini P.E.
        • Maccherini M.
        • Guideri F.
        • Lisi G.
        • Acampa M.
        • et al.
        Pravastatin treatment-associated reduction in plasma homocysteine in heart-transplanted patients.
        Transplant Proc. 2002; 34: 1273-1274
        • Rizos E.
        • Bairaktari E.
        • Kostoula A.
        • Hasiotis G.
        • Achimastos A.
        • Ganotakis E.
        • et al.
        The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.
        J. Cardiovasc. Pharmacol. Ther. 2003; 8: 127-134
        • Ridker P.M.
        • Shih J.
        • Cook T.J.
        • Clearfuld M.
        • Downs J.R.
        • Pradhan A.D.
        • et al.
        Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events.
        Circulation. 2002; 105: 1776-1779
        • Brown B.G.
        • Zhao X.Q.
        • Chait A.
        • Fisher L.D.
        • Cheung M.C.
        • Morse J.S.
        • et al.
        Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
        N. Engl. J. Med. 2001; 345: 1583-1592
        • Wang W.
        • Basinger A.
        • Neese R.A.
        • Shane B.
        • Myong S.A.
        • Christiansen M.
        • et al.
        Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production.
        Am. J. Physiol. Endocrionol. Metab. 2001; 43: E540-E547
        • Tonstad S.
        • Knudtzon J.
        • Sivertsen M.
        • Refsum H.
        • Ose L.
        Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia.
        J. Pediatr. 1996; 129: 42-49